Skip To Main Content

Questions?1-833-393-4363

*After 4 initial monthly eye injections, your doctor will choose a schedule of 1 to 4 months based on patient response during your first year of treatment. Dosing may vary.

*After 4 initial monthly eye injections, your doctor will choose a schedule of 1 to 4 months based on patient response during your first year of treatment. Dosing may vary.

^†Verana Health^® data October 2024.

Audio of pronunciation of VABYSMO

Why VABYSMO might be right for you

Eye chart (graphic)

Improves vision quickly with results maintained after 1 year of treatment^‡

Calendar (graphic)

Delivers a chance for up to 4 months between treatments^§

Two ways (graphic)

VABYSMO is the only FDA-approved treatment thought to block 2 causes of wet AMD^¶

WATCH THE VIDEO

View transcript

Hero VO:

With Wet AMD, I worry I’m losing sight of the world around me. But now, I can open up my world with VABYSMO.

VABYSMO is the first FDA-approved treatment for people with wet AMD that improves vision and delivers a chance for up to 4 months between treatments, so I can do more of what I love. VABYSMO works differently, it’s the only treatment thought to block 2 causes of wet AMD.

Announcer VO:

VABYSMO is an eye injection. Don’t take it if you have an infection, active eye swelling, or are allergic to it. VABYSMO could cause eye infection, retinal detachment, temporary increase in eye pressure, an uncommon risk of heart attack or stroke, or severe swelling of blood vessels in the eye. Report changes to vision or eye pain to your retina specialist right away.

Hero VO:

Open up your world with VABYSMO.

Announcer VO:

The #1 prescribed treatment for wet AMD. Ask a retina specialist about VABYSMO.

Ask your retina specialist about the benefits of treatment with VABYSMO (vah-BUYS-mo)

^‡In clinical trials of 665 people on VABYSMO and 664 people on aflibercept 2 mg, people gained an average of 5 letters on an eye chart at 1 month for both treatments. On average, people gained and maintained 6 letters over 1 year with VABYSMO, similar to aflibercept 2 mg.

^§After 4 initial monthly eye injections, your doctor will choose a schedule of 1 to 4 months based on patient response during your first year of treatment. Dosing may vary.

^¶VABYSMO is thought to block the VEGF and Ang-2 proteins. The benefit of blocking Ang-2 has yet to be established.

Ang-2=angiopoietin-2; VEGF=vascular endothelial growth factor.

With VABYSMO, I’m not having to run back and forth for my injections as much as I was. We have more time to do things now with the family.

Larry, a wet AMD patient being treated with VABYSMO since April 2022

Patient experiences may vary.

Watch Larry’s vision journey

Discover more

LEARN ABOUT WET AMD

LEARN ABOUT VABYSMO

What is VABYSMO?

VABYSMO (faricimab-svoa) is a prescription medicine given by injection into the eye used to treat adults with neovascular (wet) age-related macular degeneration (AMD), diabetic macular edema (DME), and macular edema following retinal vein occlusion (RVO).

Do not receive VABYSMO if you:

Have an infection in or around your eye.
Have active swelling around your eye that may include pain and redness.
Are allergic to VABYSMO or any of the ingredients in VABYSMO.

What is the most important information I should know about VABYSMO?

Injections like the one for VABYSMO can cause an eye infection (endophthalmitis), separation of layers of the retina (retinal detachment), or inflammation in the eye that can lead to vision loss. Call your healthcare provider right away if your eye becomes red, sensitive to light, or you have a change or loss of vision.
VABYSMO may cause a temporary increase in pressure in the eye (intraocular pressure), which occurs within 60 minutes after receiving the eye injection.
Although not common, VABYSMO patients have had serious, sometimes fatal, problems related to blood clots, such as heart attacks or strokes (thromboembolic events). In clinical studies for wet AMD during the first year, 7 out of 664 patients treated with VABYSMO reported such an event. In clinical studies for DME from baseline to week 100, 64 out of 1,262 patients treated with VABYSMO reported such an event. In clinical studies for RVO during 6 months, 7 out of 641 patients treated with VABYSMO reported such an event.
Severe inflammation of vessels in the retina has happened for patients treated with VABYSMO. Call your healthcare provider immediately if you experience a change in vision.

Before receiving VABYSMO, tell your healthcare provider about all of your medical conditions, including if you:

Are pregnant or plan to become pregnant. Based on how VABYSMO interacts with your body, there may be a potential risk to your unborn baby. You should use birth control before your first injection, during your treatment with VABYSMO, and for 3 months after your last dose of VABYSMO.
Are breastfeeding or plan to breastfeed. It is not known if VABYSMO passes into your breast milk. Talk to your healthcare provider about the best way to feed your baby if you receive VABYSMO.
Are taking any medications, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Tell your healthcare provider about all the medicines you take.

What should I avoid while receiving VABYSMO?

Your vision may be impaired after receiving an eye injection or after an eye exam. Do not drive or use machinery until your vision has recovered sufficiently.

What are the most common side effects with VABYSMO?

The most common side effects with VABYSMO were cataract and blood on the white of the eye (conjunctival hemorrhage).
These are not all the possible side effects of VABYSMO.

Call your healthcare provider for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088. You may also report side effects to Genentech at 1-888-835-2555.

Please see the VABYSMO full Prescribing Information for additional Important Safety Information.